Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized, double-blind, multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 345-355

  Cepeda, Jorge A ^a   Whitehouse, Tony ^b   Cooper, Ben ^a,c   Hails, Janeane ^b   Jones, Karen ^c   Kwaku, Felicia ^b   Taylor, Lee ^c   Hayman, Samantha ^a   Shaw, Steven ^c   Kibbler, Christopher ^c   Shulman, Robert ^a   Singer, Mervyn ^b   Wilson, A Peter R ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Bloodstream infections; Methicillin resistant Staphylococcus aureus; Methicillin susceptible Staphylococcus aureus; MRSA; MSSA

Indexed keywords

AMIKACIN; AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; HEMOGLOBIN; IMIPENEM; INOTROPIC AGENT; LINEZOLID; MEROPENEM; METICILLIN; METRONIDAZOLE; OXACILLIN; PIPTAZO BACTAM; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; POTASSIUM; TEICOPLANIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLEARANCE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG PENETRATION; DRUG SAFETY; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTENSIVE CARE; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MORTALITY; MUCOSA; MULTICENTER STUDY; NONHUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SKIN PENETRATION; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; CRITICAL ILLNESS; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; INTENSIVE CARE; MALE; MIDDLE AGED; OSTEOMYELITIS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; RESPIRATORY TRACT INFECTIONS; SEPSIS; SOFT TISSUE INFECTIONS; TEICOPLANIN; TREATMENT OUTCOME;

EID: 10744231747     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh048     Document Type: Article

References (42)

1. Vincent, J. L., Bihari, D., & Suter, P. M. et al. (1995). The prevalence of nosocomial infection in the intensive care units in Europe- the results of the European Prevalence of Infection in Intensive Care (EPIC) study. Journal of the American Medical Association 274, 639-44.
2. Brun-Buisson, C., Doyon, F., Carlet, J. et al. (1995). Incidence, risk factors and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. Journal of the American Medical Association 274, 968-74.
3. Pittet, D., Thiévent, B., Wenzel, R. P. et al. (1996). Bedside prediction of mortality from bacteremic sepsis. American Journal of Respiratory Critical Care Medicine 153, 684-93.
4. Friedman, G., Silva, E., & Vincent, J. L. (1998). Has the mortality of septic shock changed with time? Critical Care Medicine 26, 2078-86.
5. Diekema, D. J., Pfaller, M. A., Schmitz, F. J. et al. (2001). Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1977-1999. Clinical Infectious Diseases 32, Suppl., S114-32.
6. Hiramatsu, K., Aritaka, N., Hanaki, H. et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-3.
7. Jones, R. N., Sader, H. S., Erwin, M. E. et al. (1995). Emerging multiply-resistant enterococci among clinical isolates. Prevalence data from 97 medical center surveillance study in the United States. Diagnostic Microbiology and Infectious Disease 21, 85-93.
8. Sieradsky, K., Villari, P., & Tomasz, A. (1998). Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrobial Agents and Chemotherapy 42, 100-7.
9. Public Health Laboratory Service. (2001). Staphylococcus aureus bacteraemia: England and Wales January to December 2000. Communicable Disease Report Weekly 11, 3-5.
10. Livermore, D. M. (2000). Epidemiology of antibiotic resistance. Intensive Care Medicine 26, S14-21.
11. McGowan, J. E., Jr (2001). Increasing threat of Gram-positive bacterial infections in the intensive care unit setting. Critical Care Medicine 29, Suppl., N69-74.
12. National Nosocomial Infections Surveillance. (1999). National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999. American Journal of Infection Control 27, 520-32.
13. Arakawa, Y., Ike, Y., Nagasawa, M. et al. (2000). Trends in antimicrobial-drug resistance in Japan. Emerging Infectious Diseases 6, 572-5.
14. Anonymous. (2002). Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. Morbidity and Mortality Weekly Report 51, 902.
15. Low, D. E., Keller, N., Barth, A. et al. (2001). Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of Enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, S133-45.
16. Carbon, C. (1999). Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy 44, Topic A, 31-6.
17. Perry, C. M. & Jarvis, B. (2001). Linezolid a review of its use in the management of Serious Gram-Positive Infections. Drugs 61, 525-51.
18. Henwood, C. J., Livermore, D. M., Johnson, A. P. et al. (2000). Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. Journal of Antimicrobial Chemotherapy 46, 931-40.
19. Noskin, G. A., Siddiqui, F., Stosor, V. et al. (1999). In-vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant Enterococci. Antimicrobial Agents and Chemotherapy 43, 2059-62.
20. Stevens, D. L., Smith, L. G., Bruss, J. B. et al. (2000). Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 44, 3408-13.
21. Molinari, M. P., Garrera, G. M., Pimm, M. H. J. et al. (2000). Linezolid in the treatment of outpatients with community-acquired pneumonia: European results. European Conference Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection 6, Suppl. 1, 136.
22. Stevens, D. L., Smith, L. G., Bruss, J. B. et al. (2000) Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 44, 3408-13.
23. Birmingham, M. C., Rayner, C. R., Meagher, A. K. et al. (2003). Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clinical Infectious Diseases 36, 159-68.
24. Kuter, D. J., Phil, D. & Gleen, S. T. (2001). Hematological effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy 21, 1010-13.
25. Bone, R. C., Balk, R. A., Cerra, F. B. et al. (1977). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. Chest 101, 1644-55.
26. Rowan, K. M., Kerr, J. H., Major, E. et al. (1994). Intensive care society's acute physiology and chronic health evaluation (APACHE II) study in Britain and Ireland: a prospective, multicentre, cohort study comparing two methods for predicting outcome for adult intensive care patients. Critical Care Medicine 22, 1392-1401.
27. Vincent, J. L., Moreno, R., Takala, J. et al. (1996). The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Medicine 22, 707-10.
28. Cullen, D. J., Nemeskal, A. R., & Zaslavsky, A. M. (1994). Intermediate TISS: a new therapeutic intervention scoring system for non-ICU patients. Critical Care Medicine 22, 1406-11.
29. Maki, D. G., Weise, C. E. & Sarafin, H. W. (1977). A semiquantitative culture method for identifying intravenous-catheter-related infection. New England Journal of Medicine 296, 1305-9.
30. Diggle, P. J., Liang, K-Y. & Zeger, S. L. (1998). Analysis of Longitudinal Data. Oxford University Press, Oxford, UK.
31. Rubinstein, E., Cammarata, S. K., Oliphant, T. H. et al. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical Infectious Diseases 32, 402-12.
32. Wunderink, R. G., Cammarata, S. K., Oliphant, T. H. et al. (2003) Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clinical Therapeutics 25, 980-92.
33. Wilcox, M., Tang, T. & Hafkin, B. (2001). Linezolid versus teicoplanin for the treatment of hospitalized patients with Gram-positive infections. In Programs and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract 1481, p. 471. American Society for Microbiology, Washington, DC, USA.
34. Martin, J. P., Herberg, J. T., Slatter, J. G. et al. (1998). Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO-A), no clinical evidence of MAO-A inhibition in clinical trials has been observed. In Programs and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A-85, p. 27. American Society for Microbiology, Washington, DC, USA.
35. Mulligan, M. E., Murray-Leisure, K. A., Ribner, B. S. et al. (1993). Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. American Journal of Medicine 94, 313-28.
36. Peacock, J. M., Marsik, F. J. & Wenzel, R. P. (1980). Methicillin-resistant Staphylococcus aureus introduction and spread within a hospital. Annals of Internal Medicine 93, 526-32.
37. Geldner, G., Ruoff, M., Hoffmann, H. J. et al. (1999) Cost analysis concerning MRSA-infection in ICU. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie 34, 409-13.
38. Theaker, C., Ormond-Walshe, S., Azadian, B. et al. (2001). MRSA in the critically ill. Journal of Hospital Infection 48, 98-102.
39. Yu, V. L., Goetz, A., Wagener, M. et al. (1986). Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. New England Journal of Medicine 315, 91-6.
40. Wilson, A. P. R. (2000). Clinical pharmacokinetics of teicoplanin. Clinical Pharmacokinetics 39, 167-83.
41. Girou, E., Pujade, G., Legrand, P. et al. (1998). Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clinical Infectious Diseases 27, 543-50.
42. Corona, A., Bertolini, G., Ricotta, A. M. et al. (2003). Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. Journal of Antimicrobial Chemotherapy 52, 849-52.